Does Journavx (generic) affect renal function, and what dosing considerations are needed for patients with reduced eGFR (<15 mL/min)?

Does Journavx Affect the Kidneys?

**Journavx (suzetrigine) has not been studied in patients with severe renal impairment (eGFR <15 mL/min) and should be avoided in this population.** For patients with eGFR >15 mL/min, no dose adjustment is required, as renal function does not significantly impact drug exposure 1.

Renal Considerations for Journavx

Metabolism and Excretion Profile

Journavx is primarily eliminated through both hepatic and renal pathways:

• Fecal excretion: 49.9% (9.1% as unchanged drug, remainder as metabolites)
• Urinary excretion: 44% (primarily as metabolites)
• The drug undergoes hepatic metabolism via CYP3A to form M6-SUZ, an active metabolite that is less potent than the parent compound 1

This mixed elimination pathway means that while renal function matters, the drug is not predominantly renally cleared like some other medications.

Dosing Recommendations by Renal Function

The FDA label provides clear guidance 1:

• eGFR >15 mL/min: Standard dosing (50 mg every 12 hours) - no adjustment needed
• eGFR <15 mL/min: Avoid use - the drug has not been studied in this population

This is notably different from many renally-excreted drugs that require dose reductions across multiple eGFR thresholds. The 15 mL/min cutoff is more restrictive than typical "severe renal impairment" definitions (usually <30 mL/min) used for other medications 2, 3.

Why No Dose Adjustment for Moderate Renal Impairment?

The lack of dose adjustment for eGFR 15-60 mL/min is likely explained by:

1. Dual elimination pathways: With approximately equal hepatic and renal clearance, reduced kidney function doesn't dramatically increase drug exposure
2. Pharmacokinetic modeling: Population PK analyses showed no clinically relevant impact of renal function above 15 mL/min on suzetrigine exposure 1

This contrasts sharply with predominantly renally-cleared drugs like dabigatran (80% renal excretion) or even sofosbuvir, which require careful monitoring and dose adjustments in moderate renal impairment 4, 3.

Monitoring Recommendations

While Journavx doesn't require dose adjustment for mild-to-moderate renal impairment, baseline renal function assessment is essential:

• Before initiating therapy: Measure eGFR to ensure it's >15 mL/min
• During therapy: No specific renal monitoring frequency is mandated in the label, but general clinical practice for patients with CKD suggests:
  • Annual monitoring for stable patients with eGFR >60 mL/min 4
  • Every 6 months for eGFR 30-60 mL/min 4
  • Every 3 months for eGFR 15-30 mL/min 4

Common Pitfall to Avoid

Use the correct eGFR calculation for drug dosing decisions. The indexed eGFR (mL/min/1.73 m²) commonly reported by laboratories should be converted to non-indexed eGFR (mL/min) by adjusting for the patient's actual body surface area, particularly in patients with extreme body sizes 5, 6. However, for Journavx, since the cutoff is simply >15 vs <15 mL/min, this distinction is less critical than for drugs requiring multiple dose tiers.

Clinical Context

Journavx represents a unique pharmacologic profile as a selective NaV1.8 sodium channel blocker for acute pain management 7. Unlike opioids or NSAIDs, which have well-established renal concerns:

• NSAIDs: Can cause acute kidney injury, particularly in volume-depleted states
• Opioids: Metabolites accumulate in renal failure, increasing toxicity risk

Journavx's mixed hepatic-renal elimination and lack of dose adjustment requirements for mild-moderate CKD make it potentially advantageous in patients with some degree of renal impairment, though it remains contraindicated in severe disease (eGFR <15 mL/min).

Special Population Consideration

For patients approaching the eGFR 15 mL/min threshold or with acute kidney injury, exercise caution and consider alternative analgesics, as the safety profile in this population is unknown and drug accumulation could theoretically occur 1.